$GPRE

Green Plains stock jumps 10% on UBS price target hike By Investing.com

Green Plains Renewable Energy (NASDAQ:GPRE) shares rose about 10% after UBS analyst Manav Gupta raised its price target to $20 from $12 and kept a Neutral rating ahead of Q2 results. UBS lifted its Q2 EBITDA estimate to $93M from $36M and 2026 EBITDA to $283M from $149M, citing operational improvements and debt reduction via asset sales.

Original reporting
Published Jul 17, 2026, 6:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 17, 2026, 6:59 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefMarket movers
Primary signal
$GPRE
Bullish
medium confidence
Mentioned
$GPRE
Relevance
7/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$GPREBullishMed
01

Why it matters

Traders may use the UBS revisions as a benchmark for expectations into earnings, but should not treat it as confirmation of actual company performance.

02

Market read

A same-day analyst PT and earnings-estimate reset is driving a large single-stock move, setting a near-term expectations framework for Q2.

03

What to watch

The article highlights EBITDA estimate increases and asset optimization, but does not provide new company guidance or confirm that the operational improvements will translate into reported results.

Relevance 7/10Novelty 6/10Timing: into the company’s upcoming second-quarter results

Background

The piece attributes Green Plains’ Friday rally to a UBS analyst price-target increase and revised EBITDA forecasts ahead of its Q2 results.

Company-level read

Ticker impact

$GPREBullishMedium confidence
Context

Green Plains shares jumped 10% after UBS raised its price target to $20 from $12 and lifted EBITDA estimates ahead of Q2 results.

Expected impact

Likely supports continued upside bias or volatility into earnings, but UBS keeps a Neutral rating, limiting conviction.

Evidence & confidence

The article cites specific UBS estimate revisions (Q2 and 2026 EBITDA) and ties them to the stock’s same-day move, but it is still an analyst action rather than company-reported fundamentals.

Market effects

Read-through to renewable fuels/ethanol sentiment, with focus on operational optimization and debt reduction via asset sales.

No specific regional impact beyond the company’s Nebraska operations mentioned.

Limited; this is primarily a single-name catalyst tied to ethanol production economics.

Counterpoint

Despite the PT hike, UBS maintains Neutral, implying the upside may already be priced and that earnings execution risk remains.

Key entities

  • Green Plains Renewable Energy

    NASDAQ-listed ethanol producer whose shares rose after UBS raised its price target and EBITDA estimates.

  • UBS analyst Manav Gupta

    Raised Green Plains’ PT to $20 from $12 and increased EBITDA projections while keeping a Neutral rating.

Related articles

$GPREMed

Why Green Plains (GPRE) Stock Is Down Today

Green Plains (NASDAQ: GPRE) shares fell about 7.9% after the company reported Q2 revenue of $446.2 million, down 19.3% year over year and below analysts’ $560 million estimate. GAAP EPS was $0.83, above consensus, but the revenue miss drove sentiment. UBS previously raised its price target to $20.

$GPREMed

Green Plains (NASDAQ:GPRE) Misses Q2 CY2026 Revenue Estimates

Green Plains (NASDAQ:GPRE) reported Q2 CY2026 revenue of $446.2 million, down 19.3% year on year, missing Wall Street’s estimates. GAAP profit was $0.83 per share, 27% above analysts’ consensus. The company reported an adjusted EBITDA margin of 20.9%, up from a year earlier, and said it beat EBITDA estimates by 2.2%. Shares rose 1.3% to $16.70 after results.

$MRNAHighAI 9/10

Moderna shares soar over 50% on melanoma drug trial success

Moderna's shares rose over 50% in pre-market trading after its melanoma drug, combined with Merck's Keytruda, showed success in a Phase 3 trial. The trial met primary and key secondary endpoints, showing improved recurrence-free and metastasis-free survival. This is the first positive Phase 3 result for an mRNA-based cancer therapy. Both companies plan to present data to regulators and at medical meetings. They are also conducting trials for other cancer types.

$DLTRHigh

Why is Dollar Tree stock rising today?

Dollar Tree (DLTR) stock rose 1% in pre-market trading after Jefferies upgraded it to Hold from Underperform, raising its price target to $135 from $85. The brokerage cited improving customer foot traffic trends, with Q2 rolling foot traffic turning positive at +1.4% and July accelerating to +4.5%. Other analysts, including Raymond James and Goldman Sachs, have also recently upgraded the stock. Dollar Tree is set to report Q2 2026 earnings on August 27, with analysts expecting EPS near the top o